Simply Wall St.
Assessing Oncolytics Biotech (ONCY) Valuation After FDA Fast Track Designation For Pelareorep
📊
AI Sentiment
Positive
7/10
- Home
- ONCY
as of 02-17-2026 3:45pm EST
$0.97
$0.10
-8.97%
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
| Founded: | 1998 | Country: | N/A |
| Employees: | N/A | City: | N/A |
| Market Cap: | 94.0M | IPO Year: | N/A |
| Target Price: | $6.00 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.33 - $1.51 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered ONCY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.75%
73.75%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Oncolytics Biotech Inc. (ONCY)
Andrews Patricia S
Buy
Director
ONCY Feb 12, 2026
Avg Cost/Share
$0.86
Shares
35,400
Total Value
$30,291.78
Owned After
78,128
SEC Form 4
Seizinger Bernd R.
Buy
Director
ONCY Feb 12, 2026
Avg Cost/Share
$0.85
Shares
40,000
Total Value
$33,864.00
Owned After
566,991
SEC Form 4
Pisano Wayne
Buy
Director
ONCY Feb 12, 2026
Avg Cost/Share
$0.84
Shares
30,000
Total Value
$25,338.00
Owned After
492,414
SEC Form 4
Kelly Jared
Buy
Chief Executive Officer
ONCY Feb 12, 2026
Avg Cost/Share
$0.84
Shares
29,500
Total Value
$24,839.00
Owned After
109,000
SEC Form 4
Heineman Thomas Charles
Buy
Chief Medical Officer
ONCY Feb 12, 2026
Avg Cost/Share
$0.83
Shares
12,132
Total Value
$10,033.16
Owned After
282,818
SEC Form 4
Brown Deborah Margaret
Buy
Director
ONCY Feb 12, 2026
Avg Cost/Share
$0.85
Shares
25,000
Total Value
$21,240.00
Owned After
109,851
SEC Form 4
Hagerman Allison
Buy
VP, Product Development
ONCY Feb 12, 2026
Avg Cost/Share
$0.83
Shares
10,000
Total Value
$8,298.00
Owned After
115,059
SEC Form 4
Seizinger Bernd R.
Buy
Director
ONCY Feb 11, 2026
Avg Cost/Share
$0.83
Shares
60,000
Total Value
$49,590.00
Owned After
566,991
SEC Form 4
Kelly Jared
Buy
Chief Executive Officer
ONCY Feb 11, 2026
Avg Cost/Share
$0.84
Shares
5,600
Total Value
$4,681.60
Owned After
109,000
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Andrews Patricia S | ONCY | Director | Feb 12, 2026 | Buy | $0.86 | 35,400 | $30,291.78 | 78,128 | |
| Seizinger Bernd R. | ONCY | Director | Feb 12, 2026 | Buy | $0.85 | 40,000 | $33,864.00 | 566,991 | |
| Pisano Wayne | ONCY | Director | Feb 12, 2026 | Buy | $0.84 | 30,000 | $25,338.00 | 492,414 | |
| Kelly Jared | ONCY | Chief Executive Officer | Feb 12, 2026 | Buy | $0.84 | 29,500 | $24,839.00 | 109,000 | |
| Look Kirk | ONCY | Chief Financial Officer | Feb 12, 2026 | Buy | $0.84 | 12,000 | $10,104.00 | 287,515 | |
| Heineman Thomas Charles | ONCY | Chief Medical Officer | Feb 12, 2026 | Buy | $0.83 | 12,132 | $10,033.16 | 282,818 | |
| Brown Deborah Margaret | ONCY | Director | Feb 12, 2026 | Buy | $0.85 | 25,000 | $21,240.00 | 109,851 | |
| Hagerman Allison | ONCY | VP, Product Development | Feb 12, 2026 | Buy | $0.83 | 10,000 | $8,298.00 | 115,059 | |
| Seizinger Bernd R. | ONCY | Director | Feb 11, 2026 | Buy | $0.83 | 60,000 | $49,590.00 | 566,991 | |
| Kelly Jared | ONCY | Chief Executive Officer | Feb 11, 2026 | Buy | $0.84 | 5,600 | $4,681.60 | 109,000 |
Latest Oncolytics Biotech Inc. News
ONCY Breaking Stock News: Dive into ONCY Ticker-Specific Updates for Smart Investing
Simply Wall St.
Why Oncolytics Biotech (ONCY) Is Up 19.7% After FDA Fast Track For KRAS-Mutant Colorectal Cancer
📈
AI Sentiment
Highly Positive
8/10
Compare ONCY vs Leading Stocks
See how ONCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ONCY Oncolytics Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.